[{"id":"5ba9d628-6d23-4d5d-9027-4c4a55c8330e","acronym":"NCI-2019-08626","url":"https://clinicaltrials.gov/study/NCT04214249","created_at":"2024-01-11T17:17:48.143Z","updated_at":"2024-07-02T16:34:58.776Z","phase":"Phase 2","brief_title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04214249 - NCI-2019-08626","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • CD8 positive • CD47 expression","tags":["PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • CD8 positive • CD47 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-06-05"},{"id":"8e13ae6f-2afc-43dc-b06c-933f9e190424","acronym":"","url":"https://clinicaltrials.gov/study/NCT04093323","created_at":"2023-11-30T22:15:48.537Z","updated_at":"2024-07-02T16:35:00.203Z","phase":"Phase 2","brief_title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","source_id_and_acronym":"NCT04093323","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 08/22/2025","primary_completion_date":" 08/22/2025","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2024-05-30"},{"id":"3f558519-49f6-41cf-a5ae-3622a67f25d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04614194","created_at":"2021-01-19T20:33:11.525Z","updated_at":"2024-07-02T16:35:02.537Z","phase":"Phase 2","brief_title":"Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib","source_id_and_acronym":"NCT04614194","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" HER-2 • ER • PGR • CD8","pipe":" | ","alterations":" HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive","tags":["HER-2 • ER • PGR • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/15/2021","start_date":" 04/15/2021","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 04/15/2028","study_completion_date":" 04/15/2028","last_update_posted":"2024-05-20"},{"id":"098e0ee6-b95b-451c-a612-ce0d682ed1c8","acronym":"CheckMate-038","url":"https://clinicaltrials.gov/study/NCT01621490","created_at":"2021-01-18T06:57:16.141Z","updated_at":"2024-07-02T16:35:07.959Z","phase":"Phase 1","brief_title":"PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma","source_id_and_acronym":"NCT01621490 - CheckMate-038","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" CD8 • IFNG • CXCL10 • CXCL9 • CD4","pipe":" | ","alterations":" CD8 positive • CD4 positive","tags":["CD8 • IFNG • CXCL10 • CXCL9 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive • CD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 09/27/2012","start_date":" 09/27/2012","primary_txt":" Primary completion: 09/12/2017","primary_completion_date":" 09/12/2017","study_txt":" Completion: 10/25/2018","study_completion_date":" 10/25/2018","last_update_posted":"2024-04-23"},{"id":"fe033f7e-24b3-4288-bdd8-92b0259dd61d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010005","created_at":"2021-08-18T15:53:40.772Z","updated_at":"2024-07-02T16:35:11.477Z","phase":"Phase 1","brief_title":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","source_id_and_acronym":"NCT05010005","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Copiktra (duvelisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-04-04"},{"id":"aea0f58d-10bb-4911-b89f-8864936129e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04080804","created_at":"2021-01-18T19:58:51.916Z","updated_at":"2024-07-02T16:35:23.805Z","phase":"Phase 2","brief_title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","source_id_and_acronym":"NCT04080804","lead_sponsor":"Robert L. Ferris, MD, PhD","biomarkers":" TMB • LAG3","pipe":" | ","alterations":" CD8 positive","tags":["TMB • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 01/08/2020","start_date":" 01/08/2020","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-01-11"},{"id":"00033666-d524-4304-91c3-d4455a887688","acronym":"","url":"https://clinicaltrials.gov/study/NCT03970304","created_at":"2021-01-18T19:31:40.663Z","updated_at":"2024-07-02T16:35:26.817Z","phase":"Phase 4","brief_title":"CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults","source_id_and_acronym":"NCT03970304","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" CD8 • IFNG • TNFA","pipe":" | ","alterations":" CD8 positive","tags":["CD8 • IFNG • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 10/24/2013","start_date":" 10/24/2013","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-12-07"},{"id":"69708668-cfc0-4439-a660-502e583a10e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05483075","created_at":"2022-08-01T14:54:50.589Z","updated_at":"2024-07-02T16:35:29.781Z","phase":"","brief_title":"Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer","source_id_and_acronym":"NCT05483075","lead_sponsor":"NYU Langone Health","biomarkers":" CD8 • GZMB","pipe":" | ","alterations":" CD8 expression • CD8 positive","tags":["CD8 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD8 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/15/2022","start_date":" 11/15/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-11-09"},{"id":"b54c377f-73ac-4c27-8f1c-a96d3052690a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499795","created_at":"2023-07-03T22:09:19.913Z","updated_at":"2024-07-02T16:35:42.988Z","phase":"Phase 2","brief_title":"VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2","source_id_and_acronym":"NCT03499795","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" CD8 • TNFRSF9","pipe":" | ","alterations":" CD8 positive","tags":["CD8 • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bizalimogene ralaplasmid (VGX-3100)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 05/15/2018","start_date":" 05/15/2018","primary_txt":" Primary completion: 06/16/2020","primary_completion_date":" 06/16/2020","study_txt":" Completion: 05/26/2021","study_completion_date":" 05/26/2021","last_update_posted":"2023-07-14"},{"id":"f2ecb7df-f00d-44ff-87c8-7ca1763ca133","acronym":"JAVELIN Ovarian 200","url":"https://clinicaltrials.gov/study/NCT02580058","created_at":"2021-01-18T12:30:43.015Z","updated_at":"2024-07-02T16:35:43.530Z","phase":"Phase 3","brief_title":"A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)","source_id_and_acronym":"NCT02580058 - JAVELIN Ovarian 200","lead_sponsor":"Pfizer","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression • CD8 positive","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • pegylated liposomal doxorubicin • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 566","initiation":"Initiation: 12/21/2015","start_date":" 12/21/2015","primary_txt":" Primary completion: 09/19/2018","primary_completion_date":" 09/19/2018","study_txt":" Completion: 07/12/2022","study_completion_date":" 07/12/2022","last_update_posted":"2023-07-10"},{"id":"2c6224b1-6f93-44a7-ab06-1118d56ce71d","acronym":"WIRE","url":"https://clinicaltrials.gov/study/NCT03741426","created_at":"2021-01-18T18:19:37.462Z","updated_at":"2024-07-02T16:35:46.207Z","phase":"Phase 2","brief_title":"WIRE - Novel Treatments in Renal Cell Cancer","source_id_and_acronym":"NCT03741426 - WIRE","lead_sponsor":"CCTU- Cancer Theme","biomarkers":" CD8 • IL2","pipe":" | ","alterations":" CD8 positive","tags":["CD8 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2023-06-07"},{"id":"bd894064-6aab-4559-82a9-5826efbdaeec","acronym":"","url":"https://clinicaltrials.gov/study/NCT01291420","created_at":"2021-01-18T05:14:41.709Z","updated_at":"2024-07-02T16:35:48.201Z","phase":"Phase 1/2","brief_title":"Dendritic Cell Vaccination for Patients With Solid Tumors","source_id_and_acronym":"NCT01291420","lead_sponsor":"University Hospital, Antwerp","biomarkers":" HER-2 • KRAS • PGR • CD8 • WT1","pipe":" | ","alterations":" HER-2 negative • RAS wild-type • CD8 positive","tags":["HER-2 • KRAS • PGR • CD8 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • RAS wild-type • CD8 positive"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 05/03/2010","start_date":" 05/03/2010","primary_txt":" Primary completion: 04/25/2016","primary_completion_date":" 04/25/2016","study_txt":" Completion: 05/05/2018","study_completion_date":" 05/05/2018","last_update_posted":"2023-05-12"},{"id":"81067204-8e84-443b-84b4-cb868303afbd","acronym":"MECORA","url":"https://clinicaltrials.gov/study/NCT03359681","created_at":"2021-01-18T16:34:45.456Z","updated_at":"2024-07-02T16:36:16.095Z","phase":"Phase 2","brief_title":"Metformin Treatment for Colon Cancer","source_id_and_acronym":"NCT03359681 - MECORA","lead_sponsor":"Zealand University Hospital","biomarkers":" CD8 • CASP3","pipe":" | ","alterations":" CD8 positive","tags":["CD8 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 09/02/2021","primary_completion_date":" 09/02/2021","study_txt":" Completion: 10/04/2021","study_completion_date":" 10/04/2021","last_update_posted":"2022-03-03"},{"id":"c44a6cab-ac90-4d0f-9d10-7a9e08c17a8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05044728","created_at":"2021-09-16T15:55:19.652Z","updated_at":"2024-07-02T16:36:24.410Z","phase":"Phase 2","brief_title":"Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.","source_id_and_acronym":"NCT05044728","lead_sponsor":"Sichuan Cancer Hospital and Research Institute","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2021-09-15"},{"id":"1ca2a51c-f754-409a-a51a-fb867466fe1c","acronym":"CIRCUIT","url":"https://clinicaltrials.gov/study/NCT03453164","created_at":"2021-01-18T17:01:42.036Z","updated_at":"2024-07-02T16:36:43.237Z","phase":"Phase 1/2","brief_title":"Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)","source_id_and_acronym":"NCT03453164 - CIRCUIT","lead_sponsor":"Fukushima Medical University","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression • CD8 positive","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 41","initiation":"Initiation: 03/28/2018","start_date":" 03/28/2018","primary_txt":" Primary completion: 01/14/2021","primary_completion_date":" 01/14/2021","study_txt":" Completion: 02/28/2021","study_completion_date":" 02/28/2021","last_update_posted":"2020-07-15"},{"id":"35c340c8-d731-4058-871a-a57a6cf10a7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00266110","created_at":"2021-01-18T00:54:21.188Z","updated_at":"2024-07-02T16:37:06.984Z","phase":"Phase 2","brief_title":"Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT00266110","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" HER-2 • CD8 • IFNG","pipe":" | ","alterations":" HER-2 expression • CD8 positive","tags":["HER-2 • CD8 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • vinorelbine tartrate • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 12/01/2005","start_date":" 12/01/2005","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":" Completion: 10/27/2017","study_completion_date":" 10/27/2017","last_update_posted":"2018-09-12"},{"id":"ef479cbf-c976-417b-a2ca-e29c70b6fea5","acronym":"PRIMED-001","url":"https://clinicaltrials.gov/study/NCT02993991","created_at":"2021-01-18T14:43:45.398Z","updated_at":"2024-07-02T16:37:15.170Z","phase":"Phase 1","brief_title":"Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity","source_id_and_acronym":"NCT02993991 - PRIMED-001","lead_sponsor":"University Health Network, Toronto","biomarkers":" PD-L1 • CD8 • CD4","pipe":" | ","alterations":" CD8 positive","tags":["PD-L1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • mocetinostat (MGCD0103)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/10/2017","start_date":" 10/10/2017","primary_txt":" Primary completion: 12/21/2017","primary_completion_date":" 12/21/2017","study_txt":" Completion: 12/21/2017","study_completion_date":" 12/21/2017","last_update_posted":"2017-12-29"},{"id":"874be840-7f7b-4a55-870b-750fb167bdbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01989559","created_at":"2021-02-22T18:04:28.207Z","updated_at":"2024-07-02T16:37:41.329Z","phase":"Phase 1","brief_title":"Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery","source_id_and_acronym":"NCT01989559","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 10/01/2002","start_date":" 10/01/2002","primary_txt":" Primary completion: 09/01/2013","primary_completion_date":" 09/01/2013","study_txt":" Completion: 09/01/2013","study_completion_date":" 09/01/2013","last_update_posted":"2015-01-26"}]